VEGFA and NF2-related schwannomatosis: However, unlike neurofibromatosis type II-related VS, for which there are monoclonal antibody angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF), sporadic VS has no suitable drug treatment so far, which is related to the great variability in the growth rate and size of sporadic VS (Taurone et al., 2015).